madopar

01/01/1996 - "In this Danish-Norwegian randomized double-blind parallel-group multicentre study, we compared the therapeutic response of slow-release Madopar HBS to standard Madopar in 134 de novo patients with idiopathic Parkinson's disease during a 5-year period"
12/01/1989 - "A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease."
01/01/1987 - "Eleven patients suffering from idiopathic Parkinson's disease participated in an open study of Madopar HBS"
01/01/1987 - "The clinical effects and pharmacokinetic profiles of single doses of Madopar HBS were compared with those of standard Madopar in two studies in patients with Parkinson's disease and 'on-off' fluctuations"
01/01/1987 - "Overall results are sufficiently encouraging to warrant further controlled studies with Madopar HBS in what has been a relatively neglected area of distress for many patients with Parkinson's disease."
Get all the results and reference details, order at left...

01/01/1987 - "Thirteen patients returned to their previous standard Madopar treatment after deterioration of parkinsonian symptoms or increase of dyskinesia under the HBS treatment"
01/01/1987 - "In one female patient the dose of Madopar had to be reduced due to the development of dyskinesias"
11/01/1989 - "End-of-dose failure, which had developed in 4 patients, and peak-dose dyskinesias present in 6 patients during treatment with standard Madopar, improved significantly with Sinemet CR"
01/01/1987 - "The aim of the study is to ascertain whether a reduction of other antiparkinsonian medication, especially Madopar, can be achieved with deprenyl, in order to minimize the known late undesirable collateral effects ("on-off"-phenomena, dyskinesias)"
02/01/1992 - "Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side"
Get all the results and reference details, order at left...

03/01/1978 - "Almost all patients showed great reduction in nausea and vomiting with both Madopa and Sinemet"
01/01/1992 - "A more efficient inhibition of dopamine formation from levodopa (resulting in higher 3-OMD levels) by Madopar HBS was consistent with the superior tolerability (especially for initial nausea) observed for the Madopar HBS formulation as compared to Sinemet CR."
03/01/1978 - "A sixteen-week study examined the effect of Madopa and Sinemet on patients with Parkinson disease disease suffering nausea or vomiting as side-effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease"
Get all the results and reference details, order at left...

03/01/1978 - "Almost all patients showed great reduction in nausea and vomiting with both Madopa and Sinemet"
03/01/1978 - "A sixteen-week study examined the effect of Madopa and Sinemet on patients wi